Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients
{{output}}
Tacrolimus, a calcineurin inhibitor with a narrow therapeutic index, requires precise dosing to optimize efficacy and minimize adverse effects in kidney transplant recipients. Although CYP3A5 genetic variants influence tacrolimus pharmacokinetics, they do not ... ...
